ADMP - Adamis Pharmaceuticals GAAP EPS of -$0.03 revenue of $1.51M
- Adamis Pharmaceuticals press release ( NASDAQ: ADMP ): Q3 GAAP EPS of -$0.03.
- Revenue of $1.51M (+98.7% Y/Y).
- Cash and cash equivalents as of September 30, 2022 were approximately $2.4 million.
- Shares -1.72% AH.
For further details see:
Adamis Pharmaceuticals GAAP EPS of -$0.03, revenue of $1.51M